{"blog": [], "keywords": [{"value": "Valeant Pharmaceuticals International Inc", "name": "organizations", "rank": "1", "is_major": "Y"}, {"value": "Executive Compensation", "name": "subject", "rank": "2", "is_major": "Y"}, {"value": "Pearson, John Michael (1959- )", "name": "persons", "rank": "3", "is_major": "Y"}, {"value": "Securities and Exchange Commission", "name": "organizations", "rank": "4", "is_major": "N"}, {"value": "Mergers, Acquisitions and Divestitures", "name": "subject", "rank": "5", "is_major": "N"}], "web_url": "http://www.nytimes.com/2016/06/01/business/c-michael-pearson-former-valeant-chief-to-receive-9-million-severance.html", "document_type": "article", "byline": {"person": [{"lastname": "THOMAS", "firstname": "Katie", "role": "reported", "organization": "", "rank": 1}], "original": "By KATIE THOMAS"}, "type_of_material": "News", "multimedia": [{"url": "images/2016/06/01/business/01valeant/01valeant-thumbWide.jpg", "legacy": {"wide": "images/2016/06/01/business/01valeant/01valeant-thumbWide.jpg", "wideheight": "126", "widewidth": "190"}, "subtype": "wide", "type": "image", "width": 190, "height": 126}, {"url": "images/2016/06/01/business/01valeant/01valeant-articleLarge.jpg", "legacy": {"xlarge": "images/2016/06/01/business/01valeant/01valeant-articleLarge.jpg", "xlargeheight": "400", "xlargewidth": "600"}, "subtype": "xlarge", "type": "image", "width": 600, "height": 400}, {"url": "images/2016/06/01/business/01valeant/01valeant-thumbStandard.jpg", "legacy": {"thumbnail": "images/2016/06/01/business/01valeant/01valeant-thumbStandard.jpg", "thumbnailheight": "75", "thumbnailwidth": "75"}, "subtype": "thumbnail", "type": "image", "width": 75, "height": 75}], "section_name": "Business Day", "word_count": "340", "source": "The New York Times", "subsection_name": null, "lead_paragraph": "J. Michael Pearson stepped down amid a series of investigations into Valeant\u2019s business practices.", "pub_date": "2016-06-01T00:00:00Z", "news_desk": "Business", "headline": {"print_headline": "Valeant\u2019s Ex-Chief Is Given $9 Million in Severance Pay", "main": "Valeant\u2019s Former C.E.O. to Receive $9 Million Severance"}, "print_page": "2", "snippet": "J. Michael Pearson stepped down amid a series of investigations into Valeant\u2019s business practices.", "_id": "574db35738f0d826276783fa", "slideshow_credits": null, "abstract": "Valeant Pharmaceuticals announces former chief executive J Michael Pearson will receive $9 million severance payment and will continue on in capacity of consultant until end of 2017; Pearson left company due to number of investigations into company's business practices."}